Screener / SEC EDGAR /CIK 0000856982 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

Merit Medical Systems Inc MMSI

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 24, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+34.7%

The MD&A has no sentence that names a cause for this change.

Gross margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

47.4% to 48.7% (+1.3 pts)

“The increase in gross profit as a percentage of sales for 2025, as compared to 2024, was primarily due to favorable changes in pricing and product mix, partially offset by higher intangible amortization expense as a percentage of sales associated with acquisitions and unfavorable manufacturing variances.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+11.8%

“The increase in our domestic sales in 2025 was driven primarily by our U.S. direct, endoscopy, and OEM businesses.”

Read it in the 10-K

“The increase in our international sales during 2025 was primarily a result of higher sales in EMEA, which increased $37.9 million or 15.3%, higher Rest of World (“ROW”) sales which increased $7.0 million or 12.2%, and higher sales in our Asia Pacific region, which increased $5.8 million or 2.3%, compared to the corresponding period of 2024.”

Read it in the 10-K

Operating margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

11.5% to 12.2% (+0.7 pts)

“This increase in cardiovascular operating income was primarily related to increased sales and gross profit, partially offset by increased SG&A and R&D expenses.”

Read it in the 10-K

Net income

Change, FY to Dec 31, 2025 vs Dec 31, 2024

+6.8%

“The increase in net income for 2025, when compared to 2024, was primarily related to higher sales and higher gross margin as a percentage of sales; partially offset by higher SG&A, R&D, other expense and income tax expense.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +11.8%

    “The increase in our domestic sales in 2025 was driven primarily by our U.S. direct, endoscopy, and OEM businesses.”

    Read it in the FY 2025 10-K

    “The increase in our international sales during 2025 was primarily a result of higher sales in EMEA, which increased $37.9 million or 15.3%, higher Rest of World (“ROW”) sales which increased $7.0 million or 12.2%, and higher sales in our Asia Pacific region, which increased $5.8 million or 2.3%, compared to the corresponding period of 2024.”

    Read it in the FY 2025 10-K
  • FY 2024 +7.9%

    “The increase in our domestic sales in 2024 was driven primarily by our U.S. direct, OEM and endoscopy businesses.”

    Read it in the FY 2024 10-K

    “The increase in our international sales during 2024 was primarily a result of higher sales in EMEA, which increased $11.2 million or 4.8%, higher ROW sales which increased $8.9 million or 18.1%, and higher sales in our Asia Pacific region, which increased $5.3 million or 2.1%, compared to the corresponding period of 2023.”

    Read it in the FY 2024 10-K

Gross margin

2 of 2 years explained
  • FY 2025 +1.3 pts

    “The increase in gross profit as a percentage of sales for 2025, as compared to 2024, was primarily due to favorable changes in pricing and product mix, partially offset by higher intangible amortization expense as a percentage of sales associated with acquisitions and unfavorable manufacturing variances.”

    Read it in the FY 2025 10-K
  • FY 2024 +1.0 pts

    “The increase in gross profit as a percentage of sales for 2024, as compared to 2023, was primarily due to increased sales combined with favorable changes in standard costs and product mix, partially offset by higher intangible amortization expense as a percentage of sales associated with acquisitions.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 +0.7 pts

    “This increase in cardiovascular operating income was primarily related to increased sales and gross profit, partially offset by increased SG&A and R&D expenses.”

    Read it in the FY 2025 10-K
  • FY 2024 +1.6 pts

    “This increase in cardiovascular operating income was primarily related to higher sales and gross profit, decreased acquired in-process research and development charges, and decreased contingent consideration expense ($0.4 million in 2024 compared to $1.7 million in 2023), partially offset by higher SG&A and R&D expenses.”

    Read it in the FY 2024 10-K

Net income

2 of 2 years explained
  • FY 2025 +6.8%

    “The increase in net income for 2025, when compared to 2024, was primarily related to higher sales and higher gross margin as a percentage of sales; partially offset by higher SG&A, R&D, other expense and income tax expense.”

    Read it in the FY 2025 10-K
  • FY 2024 +27.5%

    “The increase in net income for 2024, when compared to 2023, was primarily related to higher sales, higher gross margin as a percentage of sales, decreased contingent consideration expense ($0.4 million in 2024 compared to $1.7 million in 2023), decreased acquired in-process research and development expense ($0 in 2024 compared to $1.6 million in 2023) and decreased other expenses; partially offset by higher SG&A, R&D, and income tax expense.”

    Read it in the FY 2024 10-K

Cash from operations

0 of 2 years explained
  • FY 2025 +34.7%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +52.1%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MMSI/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.